Hunter Chen, PhD is an Associate Director in Formulation Development at Regeneron Pharmaceuticals. Having over 10 years of experience in the biopharmaceutical industry, Hunter leads a team responsible for developing technologies for Drug Substance and Drug Product, including controlled release formulations. A focus area for his team is ocular drug delivery to address unmet needs of patients with serious diseases of the eye. His prior work experience include intellectual property consulting and performing due diligence for venture capital investors. Hunter received his PhD and MSE in Biomedical Engineering from Johns Hopkins University and his BS in Bioengineering from The University of California, Berkeley. He is a CRS member, current board member on the CRS Ocular Delivery Focus Group, and past recipient of the CRS/Elsevier Journal of Controlled Release Jorge Heller Award.